| Literature DB >> 34420153 |
Inge A T van de Luitgaarden1, Sabine van Oort2, Emma J Bouman3, Linda J Schoonmade4, Ilse C Schrieks5,6, Diederick E Grobbee5,6, Yvonne T van der Schouw5, Susanna C Larsson7,8, Stephen Burgess9,10, Adriana J van Ballegooijen3,11, N Charlotte Onland-Moret5, Joline W J Beulens5,3.
Abstract
The causal effects of alcohol-in-moderation on cardiometabolic health are continuously debated. Mendelian randomization (MR) is an established method to address causal questions in observational studies. We performed a systematic review of the current evidence from MR studies on the association between alcohol consumption and cardiometabolic diseases, all-cause mortality and cardiovascular risk factors. We performed a systematic search of the literature, including search terms on type of design and exposure. We assessed methodological quality based on key elements of the MR design: use of a full instrumental variable analysis and validation of the three key MR assumptions. We additionally looked at exploration of non-linearity. We reported the direction of the studied associations. Our search yielded 24 studies that were eligible for inclusion. A full instrumental variable analysis was performed in 17 studies (71%) and 13 out of 24 studies (54%) validated all three key assumptions. Five studies (21%) assessed potential non-linearity. In general, null associations were reported for genetically predicted alcohol consumption with the primary outcomes cardiovascular disease (67%) and diabetes (75%), while the only study on all-cause mortality reported a detrimental association. Considering the heterogeneity in methodological quality of the included MR studies, it is not yet possible to draw conclusions on the causal role of moderate alcohol consumption on cardiometabolic health. As MR is a rapidly evolving field, we expect that future MR studies, especially with recent developments regarding instrument selection and non-linearity methodology, will further substantiate this discussion.Entities:
Keywords: Alcohol consumption; Cardiovascular disease; Cardiovascular risk factors; Diabetes; Mendelian randomization; Mortality; Systematic review
Mesh:
Year: 2021 PMID: 34420153 PMCID: PMC9329419 DOI: 10.1007/s10654-021-00799-5
Source DB: PubMed Journal: Eur J Epidemiol ISSN: 0393-2990 Impact factor: 12.434
Fig. 1Overview of the Mendelian randomization design and assumptions. First assumption: the genetic variant is associated with alcohol consumption. Second assumption: the genetic variant is not associated with any confounder of the alcohol consumption-outcome association. Third assumption: the genetic variant does not affect the outcome, except possibly via its association with alcohol consumption
Fig. 2Flowchart of the selection of Mendelian randomization studies of alcohol consumption in relation to cardiovascular diseases, diabetes, mortality or cardiometabolic risk factors
Overview of the 24 included Mendelian randomization studies on alcohol consumption in relation to cardiovascular diseases, diabetes, mortality or cardiometabolic risk factors, stratified by one-sample and two-sample study design
| Ancestry | N SNPs | SNP | Study | Sample size | Male sex | Age* | Country | Outcomes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CVD | Diabetes | Mortality | Risk factors | ||||||||
| Asian | 1 | ALDH2 (rs671) | AuYeunga [ | 4867 | 100% | ≥ 50 | China | CVD, IHD | BMI, SBP, DBP, HDL-C, LDL-C, triglycerides, FG | ||
| AuYeunga [ | 4867 | 100% | ≥ 50 | China | CVD, IHD | SBP, DBP, HDL-C, LDL-C, triglycerides, FG | |||||
| Chenb [ | 7658 (BP) 4219 (HT) | Mixed | NA | Japan | SBP, DBP, HT | ||||||
| Choc [ | 7152 | 47% | 52 ± 8 | South Korea | CVD, CHD | DM | BMI, WC, WHR, SBP, DBP, HT, TC, HDL-C, LDL-C, TG, FG | ||||
| Jee [ | 4367 | 69% | M: 42 ± 9 F: 43 ± 11 | South Korea | FG | ||||||
| Peng [ | 4536 | 50% | 55 ± 7 | China | DM | BMI, WC, WHR, SBP, DBP, TC, HDL-C, TG, FG; HOMA-IR; HOMA-beta; PPG | |||||
| Tabara [ | 4229 | 54% | 63 ± 11 | Japan | HDL-C, LDL-C | ||||||
| Tabara [ | 8,364 | 33% | M: 55 ± 14 F: 51 ± 13 | Japan | HDL-C, LDL-C, TG | ||||||
| Taylor [ | 3788 | 36% | 58 ± 11 | China | BMI, SBP, DBP, TC, HDL-C, LDL-C, TG, FG | ||||||
| Zhao [ | 2349 | 46% | 59 ± 11 | China | BMI, weight, WC, SBP, DBP, HT, TC, HDL-C, LDL-C, TG | ||||||
| Chocd [ | 2011 | 67% | 56 ± 7 | South Korea | SBP, DBP, HT | ||||||
| 2 | ALDH2 (rs671), ADH1B (rs1229984) | ||||||||||
| Millwood [ | 161,498 | 41% | 52 ± 11 | China | AMI, CHD, stroke | BMI, weight, WC, WHR, SBP, DBP, HDL-C, LDL-C, TG, NFG | |||||
| European | 1 | ADH1B (rs1229984) | Almeida [ | 3496 | 100% | 77 ± 4 | Australia | All-cause | |||
| Holmese [ | 261,991 | 52% | 58 (26; 75) | Europe and North America | CHD, stroke | T2DM | BMI, WC, SBP, DBP, HT, HDL-C, TG, FG | ||||
| Silverwoode [ | 80,057 | NA | NA | Europe and North America | BMI, WC, SBP, HDL-C, TG | ||||||
| 2 | ADH1B (rs1229984), ADH1C (rs698) | Christensen [ | 74,632 | 45% | 57 (20; 99) | Denmark | Stroke | ||||
| Lawlor [ | 54,604 | 43% | 56 ± 13 | Denmark | BMI, SBP, DBP, HDL-C, TG, NFG | ||||||
| 5 | ADH1B (rs2066702 and rs1693457), ADH1B/1C (rs1789891), ADH1C (rs698), ADH4 (rs1126671) | Vue [ | 10,893 | 47% | 54 ± 6 | United States (European Americans) | TC, HDL-C, LDL-C, TG | ||||
*Age (years) displayed as mean ± SD, mean (min; max), or > min
aSame study population
bMeta-analysis applying the instrumental variable approach
cOverlapping study population
dMain analysis with only rs671 as genetic instrument; sensitivity analysis with both SNPs as genetic instrument
eOverlapping study population
AMI acute myocardial infarction, AF atrial fibrillation, BMI body mass index, CHD coronary heart disease, CVD cardiovascular disease, DBP diastolic blood pressure, DM diabetes mellitus, F women, FG fasting glucose, GSCAN GWAS & sequencing consortium of alcohol and nicotine use, HDL-C high-density lipoprotein cholesterol, HF heart failure, HOMA-IR homeostatic model assessment of insulin resistance, HOMA-beta homeostatic model assessment of beta-cell function, HT hypertension, IHD ischemic heart disease, M men, NA not available, NFG non-fasting glucose, PAD peripheral artery disease, PPG 2-h post-prandial blood glucose, SBP systolic blood pressure, SNP single nucleotide polymorphism, T2DM type 2 diabetes mellitus, TC total cholesterol, TG triglycerides, UKB UK Biobank, WC waist circumference, WHR waist-to-hip ratio
Fig. 3Methodological quality assessment of the included Mendelian randomization studies, sorted by year of publication and first author name. Please see Fig. 1 for an overview of the assumptions of a Mendelian randomization analysis. First assumption: the genetic variant is associated with alcohol consumption. Second assumption: the genetic variant is not associated with any confounder of the alcohol consumption-outcome association. Third assumption: the genetic variant does not affect the outcome, except possibly via its association with alcohol consumption. Please see Supplementary Table 1 for a more extensive overview of the methodological quality assessment
Overview of the associations of higher genetically predicted alcohol consumption with cardiovascular disease, diabetes and mortality in Mendelian randomization studies
| Outcome and study | Ancestry | IV | Effect measure and unit | Association with outcome | ||
|---|---|---|---|---|---|---|
| Total | Men | Women | ||||
| AuYeung* [ | Asian | No | OR GA versus AA genotype | 1.14 (0.73; 1.79) | ||
| AuYeung* [ | Asian | Yes | OR per 10 g/day | 0.98 (0.76; 1.27) | ||
| Cho [ | Asian | Yes | OR per g/day | 0.95 (0.88; 1.03) | 0.99 (0.97; 1.01) | 1.21 (0.83; 1.76) |
| Millwood [ | Asian | Yes | RR per 280 g/week | 0.96 (0.78; 1.18) | 0.94 (0.74; 1.20) | |
| Ischemic heart disease/coronary heart disease | ||||||
| AuYeung* [ | Asian | No | OR GA versus AA genotype | 1.48 (0.84; 2.61) | ||
| AuYeung* [ | Asian | Yes | OR per 10 g/day | 1.10 (0.83; 1.45) | ||
| Cho [ | Asian | Yes | OR per g/day | 0.98 (0.89; 1.09) | 0.99 (0.97; 1.02) | 1.00 (0.61; 1.62) |
| Holmes [ | European | No | OR GG versus AA or AG | |||
| Larsson [ | European | Yes | OR per 1-SD increase in log-transformed drinks/week | 1.16 (1.00; 1.36) | ||
| Millwood [ | Asian | Yes | RR per 280 g/week | 1.05 (0.94; 1.17) | 1.02 (0.93; 1.12) | |
| Jianga [ | European | Yes | OR per 1-SD increase in drinks/week | 1.00 (0.77; 1.32) | ||
| Larssona [ | European | Yes | OR per 1-SD increase in log-transformed drinks/week | 1.17 (1.00; 1.37) | ||
| Larsson [ | European | Yes | OR per 1-SD increase in log-transformed drinks/week | |||
| Larssonb [ | European | Yes | OR per 1-SD increase in log-transformed drinks/week | 1.00 (0.68; 1.47) | ||
| Van Oortb [ | European | Yes | OR per 1-SD increase in log-transformed drinks/week | 1.11 (0.85; 1.46) | ||
| Christensen [ | European | Yes | HR slow versus fast metabolizers | 1.15 (0.66; 2.02) | ||
| Holmes [ | European | No | OR GG versus AA or AG | 1.02 (0.93; 1.11) | ||
| Millwood [ | Asian | Yes | RR per 280 g/week | 0.98 (0.88; 1.09) | ||
| Larsson [ | European | Yes | OR per 1-SD increase in log-transformed drinks/week | |||
| Cho [ | Asian | Yes | OR per g/day | 1.05 (0.99; 1.10) | 1.02 (1.00; 1.04) | 0.97 (0.77; 1.22) |
| Holmes [ | European | No | OR GG versus AA or AG | 0.98 (0.92; 1.05) | ||
| Peng [ | Asian | Yes | Incidence rate ratio for 22 g increase in log-transformed alcohol | 1.40 (0.67; 2.93) | ||
| Yuan [ | European | Yes | OR per drinks/week | 1.08 (0.80; 1.45) | ||
| Almeida [ | European | No | HR non-carriers versus A-allele carriers | |||
| Van Oort [ | European | Yes | OR per 1-SD increase in log-transformed drinks/week | 0.87 (0.55; 1.38) | ||
*Same study population
aThese two studies for atrial fibrillation had overlapping study populations
bThese two studies for heart failure had overlapping study populations
The results presented here are the results of the linear analyses. Detrimental associations have been displayed in bold
IV instrumental variable analysis
The associations dispalyed bold are detrimental associations